$54.90
1.15 (+2.14%)
Gilead Sciences, Inc. (NASDAQ:GILD)
CAPS Rating:
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
Gilead is a leader in HIV treatment and the company also receives royalties from Roche for Tamiflu, a treatment for
influenza. The new US administration is committed to increase spending for HIV diagnosis and treatment.
Generic drug competition will clearly weigh on pharma, but Gilead's superior market positioning is worth paying for.